“数理论坛”第87期：Mathematical modeling about the scheduling of VEGF and PD-1 inhibitors in combination cancer therapy
发布人：毕洁发表时间：2019-04-11点击：次
数理论坛第87期
报告题目
Mathematical modeling about the scheduling of VEGF and PD-1 inhibitors in combination cancer therapy
报告时间
2019年4月12日（周五）14：00-16：00
报告地点
东区教学综合楼A1404
报告人
赖秀兰 （中国人民大学数学学院）博士
报告人
简介
赖秀兰，博士毕业于加拿大西安大略大学应用数学系，2014-2018年期间在中国人民大学数学科学研究院和美国俄亥俄州立大学生物数学所从事博士后研究，主要从事生物医学相关问题预测模型的模型建立、理论分析、数值模拟方面研究，包括关于癌症的数学建模，感染者体内病毒动力学研究。在PNAS, BMC System Biology, PLoS ONE, Journal of Theoretical Biology, Journal of the Royal Society Interface, SIAM Journal of Applied Math, Bulletin of Mathematical Biology, DCDS-B 等SCI核心期刊发表20篇论文。作为课题负责人主持过一项国家自然科学基金项目。
报告摘要
Abstract: One of the questions in the design of cancer clinical trials with combination of two drugs is in which order to administer the drugs. This is an important question, especially in the case where one agent may interfere with
the effectiveness of the other agent. In this talk I will address this scheduling question by mathematical modeling approaches, in a specific case where one of the drugs is anti-VEGF, which is known to affect the perfusion of other drugs. As a second drug we take anti-PD-1. Both drugs are known to increase the activation of anticancer T cells. Our simulations show that in the case where anti-VEGF reduces the perfusion, a non-overlapping schedule is significantly more effective than asimultaneous injection of the two drugs, and it is somewhat more beneficial to inject anti-PD-1 first.
